Vermillion Posts No Revenues in 2009

The company, which received FDA clearance for its OVA1 test in September and began marketing the test earlier this year, also reported a loss of $22 million in 2009.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories